Ocugen, Inc. (OCGN)

Gene Therapy Trial Reaches Progress Milestone


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
April 4, 2022
Report ID: 24664
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Ocugen, Inc.
Ocugen, Inc.
Healthcare
Biotechnology
Ticker
OCGN
Current Price
$1.61 5.92%
Market Cap
$352.4M
Price Target
Refer to Report
Volume
4.8M
52wk Range
$1.44 - $6.5
Related Research Reports
11/9/2022

3Q22 Reported With Pipeline Updates
3Q22 Reported With Pipeline Updates (OCGN)
11/2/2022

R&D Day Highlights Gene Therapy and COVID Programs
R&D Day Highlights Gene Therapy and COVID Programs (OCGN)
9/29/2022

Nasal COVID-19 Vaccine Licensed For Development
Nasal COVID-19 Vaccine Licensed For Development (OCGN)
8/8/2022

2Q22 Reported With New Pipeline Program Moving Forward
2Q22 Reported With New Pipeline Program Moving Forward (OCGN)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.